- JP-listed companies
- Cash flow
【JP:206A】Cash flow
Market cap
¥6.7B
P/E ratio
PRISM BioLab develops new drugs that target hard-to-reach protein interactions inside cells, partnering with major pharmaceutical companies like Eisai.
| 2022/09 | 2023/09 | 2024/09 | 2025/09 | |
| Depreciation & amortization | 1 | 9 | - | - |
| Cash from operations | 103 | -514 | 150 | -1,468 |
| Capital expenditures | -6 | -35 | -206 | -65 |
| Cash from investing | -8 | -40 | -244 | -69 |
| Cash from financing | 111 | - | 3,370 | 34 |
| Free cash flow | ||||
| FCF margin (%) |